

OFFICE OF HUMAN RESEARCH ETHICS

Medical School Building 52
Mason Farm Road
CB #7097
Chapel Hill, NC 27599-7097
(919) 966-3113
Web site: ohre.unc.edu
https://my.research.unc.edu for IRB status
Federalwide Assurance (FWA) #4801

**To:** Haiyan Tong Environmentally Protection Agency CB# 7315

From: Biomedical IRB

Authorized signature on behalf of IRB

**Approval Date:** 5/26/2010

Expiration Date of Approval: 1/24/2011

RE: Notice of IRB Approval by Expedited Review (under 45 CFR 46.110)

Submission Type: Unanticipated Problem

Expedited Category: Minor Change to Previously Approved Research

**Study #:** 07-0190 **Other #:** CTRC : 2579

Study Title: GCRC-2579: Cardioprotective Effects of Omega-3 Fatty Acids Supplementation in

Healthy Older Subjects Exposed to Air Pollution Particles

Sponsors: EPA Intramural Federal Research

This submission has been approved by the above IRB for the period indicated. It has been determined that the risk involved in this modification is no more than minimal. Unless otherwise noted, regulatory and other findings made previously for this study continue to be applicable.

### **Submission Description:**

A study subject (OMC-029) had intermittent atrial and ventricular ectopy. No symptoms. Submission includes details of event, as requested by IRB. No further action is needed.

## Investigator's Responsibilities:

This study was reviewed in accordance with federal regulations governing human subjects research, including those found at 45 CFR 46 (Common Rule), 45 CFR 164 (HIPAA), 21 CFR 50 & 56 (FDA), and 40 CFR 26 (EPA), where applicable.

CC:

James Samet, Environmentally Protection Agency Robert Truckner, (EPA), Non-IRB Review Contact Wanda Simmons, (CTRC), Non-IRB Review Contact

# Response to Minor Stipulations Adverse Event

| Rece                   | ipt Date  | :          | 5/25/20                 | 10                                       | osia inchesio                      | فالتعقيد فيالم فالمسائلية   |                                |   |   |                                    |                 |  | Review Type:                 | Rene  | wal Full  | Board  |
|------------------------|---|------------|-------------------------|--|------------------------------------|---|--------------------------------|---|---|------------------------------------|-----------------|--|------------------------------|---|---|--|
| IRB:                   | Biome   | edic       | al                      | waxaaxaaxaa                              | PI:                                | Haiyan To   | ng                             |   | IRE   | BID:                               | 07-019          | 0  | IRB A                        | imin :  | na Fried  | man  |
| Title:                 |   |            | 579: Ca<br>Particle     |  | ective                             | Effects of  | Ome                            | ga-3 Fa                                 | tty Acids                                     | Supp                               | lement          | ation in He  | althy Older S                | Subjects  | Expose  | d to Air   |
| II F                   | ull Boar  | d R        | leview                  | aldinizaena inizinia ki pelitinia menuha |                                    | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~  | nunga yang kelang pakan palang | t (greens ) seemandeel (southeadaile de | V   | Not Fu                             | ıll Boai        | rd Review  |                              | A CONTRACTOR OF A SECURIOR  |   |  |
| Employed engineers and | ing page and a married of a section of the page of the section of |            |                         |  | in a constitution of a reason from |   | TOTAL SALES                    | A CANADA MANAGAMA PARAMANANA PA         |   |                                    |                 | A Company of the Comp |                              | nacionalina malinidida (cinalina)<br>A Autonolita I del malingo e consultação | el partinol (A) el parles y encret a se encret.<br>Neclearité de production (Antonilla A) (Antonilla A) | poor, or programme to company to the constitution of the constitut |
| 1                      | ly Desc   |            |                         |  |                                    |   | - :                            |   | أنحية بمعارضهمين                              |                                    |                 | manga katang kalang da 1991 sa   |                              |   |   |  |
| Th<br>car              | е ригро<br>rdiac ch   | se<br>lang | of this si<br>ges in he | tudy is t<br>ealthy ol                   | o ider<br>Ider si                  | itify an opti<br>abjects. He  | mal c<br>althy                 | oncentr<br>adults,                      | ation of<br>ages 50                           | diesel<br>to 75                    | exhau<br>years, | st which ca<br>will comple   | n be used to<br>te seven vis | study t<br>ts over  | he risks<br>18-20 w   | of<br>eeks.  |
| Sub                    | missio  | n D        | escripti                | on:                                      |                                    | a no a sa a dan na mana a sa a dan na |                                |   |   |                                    |                 |  |                              |   |   |  |
| Αs                     | study su  | ıbje       | ct (OMC                 | C-029) h                                 | ad ca                              | rdiac arrhy   | thmia                          |   | according forms of magdings                   | e i naemaži v rečini               |                 |  |                              |   |   | =  |
|                        |   |            |                         |  |                                    |   |                                |   |   |                                    |                 |  |                              |   |   |  |
|                        |   |            |                         |  |                                    |   |                                |   |   |                                    |                 |  |                              |   |   |  |
|                        |   |            |                         |  |                                    |   |                                |   |   |                                    |                 |  |                              |   |   |  |
|                        |   |            |                         |  |                                    |   |                                |   |   |                                    |                 |  |                              |   |   |  |
|                        |   |            |                         |  |                                    |   |                                |   |   |                                    |                 |  | 1.                           |   |   |  |
|                        |   |            |                         |  |                                    |   |                                |   |   |                                    |                 | ,  | Nank                         | + /   | Anno  | nre  |
|                        |   |            |                         |  |                                    |   |                                |   |   |                                    |                 | ,  |                              | , ,   |   | 00 -   |
|                        |   |            |                         |  |                                    |   |                                |   |   |                                    |                 | N  | O Sur                        | Ma  | ax  | Line   |
|                        |   |            |                         |  |                                    |   |                                |   |   |                                    |                 | · ·  | Thank<br>o for               | 01000   |   | יז יקו<br>רי   |
|                        |   |            |                         |  |                                    |   |                                |   |   |                                    |                 |  |                              |   |   | A  |
|                        |   |            |                         |  |                                    |   |                                |   |   |                                    |                 |  |                              |   |   |  |
|                        |   |            |                         |  |                                    |   |                                |   |   |                                    |                 |  |                              |   |   |  |
|                        |   |            |                         |  |                                    |   |                                |   |   |                                    |                 |  |                              |   |   |  |
|                        |   |            |                         |  |                                    |   |                                |   |   |                                    |                 |  |                              |   |   |  |
|                        |   |            |                         |  |                                    | SE ONLY):   |                                |   |   |                                    | F               | INAL ACTI  | . /h <                       | 120   | /   |  |
| M. Verritorine.        |   |            | hecklist<br>lation let  |  | ted                                |   |                                |   |   |                                    | 1               | Approved<br>Approved   | d with Minor                 | Stipulat  | ions  |  |
| ľ                      | Draft   | leti       | er prepa                | ared                                     |                                    |   |                                |   |   |                                    |                 | NHSR   | C.BIDD                       | ,   |   |  |
|                        |   |            |                         |  |                                    | d (Initials/D<br>Initials/Dat   |                                | e decemen decoding free                 | , c   | indocentially desired to           | ) I.<br>) [     | Return to  |                              |   |   |  |
| Ĩ                      | Emai  | il co      | py sent                 |  |                                    |   |                                | villebboldmark.                         | kajyattija nast riiginaan kaapalpan kaayani   |                                    | ľ               | Closure  |                              |   |   |  |
| •                      | Hard<br>pprova  |            |                         |  |                                    |   |                                |   |   |                                    |                 |  |                              |   |   |  |
| ľ                      | Draft   | let        | ter prepa               |  |                                    |   |                                | n -                                     | 711/  |                                    |                 |  |                              |   |   |  |
|                        |   |            |                         |  |                                    | d (Initials/D<br>Initials/Dat   |                                | 70                                      | 144//   | <i>0</i>                           | )               |  |                              |   |   |  |
| ~ I                    | Emai  | il co      | py sent                 | or                                       |                                    |   |                                | AND STANFORM                            | h dhaffiaid an dhaidh an ann amh ibre an beir | mad d accessorate and described to | smarr.          |  |                              |   |   |  |
| W                      | 🕏 Hard  | co         | py sent                 | /  |                                    |   | æ                              |   |   |                                    |                 |  |                              |   |   |  |

Consent forms attached: Other attachments: To: IRB CB# 7097, Medical Building 52 105 Mason Farm Road Chapel Hill, NC 27599-7097 RECEIVED

MAY 2 5 2010

IRB UNC-CH

From: Haiyan Tong

**Environment Protection Agency** 

CB# 7315

E-mail: tong.haiyan@epa.gov Phone number: 966-4993

May 25, 2010

**Study #:** 07-0190 **Other #:** CTRC: 2579

Study Title: Cardioprotective Effects of Omega-3 Fatty Acids Supplementation in

Healthy Older Subjects Exposed to Air Pollution Particles

Dear IRB review committee,

Thanks for the Board Review of an unanticipated problem report submitted to IRB on May 25, 2010. Below are a point-by-point responses to the items listed in the "Contingencies to be addressed following IRB review on May 25, 2010".

What was the duration of exposure at the time the arrhythmia was noted? The subject was exposed to two-hour of filtered air which is the clean air control of the air pollution exposure study. The arrhythmia was noted on the telemetry right after the filtered air exposure began.

What was the nature and duration of the cardiac arrhythmia? Intermittent premature ventricular contraction (PVC) and supraventricular ectopy were noticed during the 2 hrs of exposure session. The Holter monitor data collected from 8 am on May 24 to 8 am on May 25 showed that the PVC and supraventricular ectopy were presented throughout the 24 hr period.

Was the subject symptomatic? The subject had no symptom with arrhythmia.

What treatment and follow up were recommended, if any?

In consideration of clean air exposure does not cause cardiac arrhythmia and the subject was symptom free, we did not treat the subject. However, the subject was counseled for his arrhythmia and provided a copy of the Holter monitor report and advised to see his own primary physician for further investigation.

Was there anything in the subject history to indicate risk or prior occurence? The subject had no history of arrhythmia. The ECG was normal on the pre-study physical exam which was evaluated by a cardiologist.

The unanticipated problem reported is specific to this subject. We do not revise the study protocol, consent forms, and recruitment materials at this time.

Please let me know if you have any further questions.

Sincerely.

Haiyan Tong

**IRB** Notice

IRB

to:

Haiyan Tong

05/25/2010 02:02 PM

Cc:

James Samet, Robert Truckner, wsimmons+IRB

Show Details

To: Haiyan Tong

**Environmentally Protection Agency** 

CB# 7315

From: Biomedical IRB

Date: 5/25/2010 RE: Contingencies to be addressed following IRB review of unanticipated problem

report

Submission Type: Unanticipated Problem

**Study #:** 07-0190 **Other #:** CTRC : 2579

Study Title: GCRC-2579: Cardioprotective Effects of Omega-3 Fatty Acids Supplementation in Healthy

Older Subjects Exposed to Air Pollution Particles

## **Submission Description:**

A study subject (OMC-029) had cardiac arrhythmia.

The IRB has reviewed your unanticipated problem report and determined that changes to the study are warranted as described below. Please address these changes in a cover memo that includes a point-by-point response to the item(s) listed and attach any revised study documents, including protocol, consent forms, recruitment materials, etc.

When you respond, please be sure to cite the IRB study number noted above, and indicate that you are responding to an unanticipated problem report. Failure to link your response to this study, in general, and this memo, in particular, may result in delays. Any additional changes beyond what has been requested (including new materials) must also be listed and discussed in the memo. Please submit 2 copies of all revised materials, one in which all changes are underlined and the other a "clean" copy with no underlining.

#### **Study Specific Details:**

Please provide additional information. What was the duration of exposure at the time the arrhythmia was noted? What was the nature and duration of the cardiac arrhythmia? Was the subject symptomatic? What treatment and follow up were recommended, if any? Was there anything in the subject history to indicate risk or prior occurence?

CC:

James Samet, Environmentally Protection Agency Robert Truckner, (EPA), Non-IRB Review Contact Wanda Simmons, (CTRC), Non-IRB Review Contact

IRB Informational Message—please do not use email REPLY to this address